OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins	80
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	70
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity	61
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders	53
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	45
Albumin-based drug designs for pharmacokinetic modulation	45
Prodrugs and nanomicelles to overcome ocular barriers for drug penetration	43
High-throughput PBTK models for in vitro to in vivo extrapolation	41
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?	38
Antibiotic resistance propagation through probiotics	36
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	35
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?	35
The pharmacokinetics of antibiotics in cystic fibrosis	34
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	32
Alterations in drug disposition in older adults: a focus on geriatric syndromes	32
Drug metabolism in the lungs: opportunities for optimising inhaled medicines	30
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease	30
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	29
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems	28
Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis	25
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs	23
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder	23
In silico models for genotoxicity and drug regulation	23
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	23
Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity	23

Genetic risk factors in the development of idiosyncratic drug-induced liver injury	22
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	21
SULT genetic polymorphisms: physiological, pharmacological and clinical implications	21
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review	21
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization	21
Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives	20
Pharmacogenetic factors affecting β-blocker metabolism and response	19
Novel strategies for the treatment of acetaminophen hepatotoxicity	19
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	19
Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients	19
Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity	19
ADME and toxicity considerations for tramadol: from basic research to clinical implications	18
PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches	18
An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs)	18
New clinical targets of d-chiro-inositol: rationale and potential applications	17
Retinoic acid receptor-targeted drugs in neurodegenerative disease	17
An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome	16
Soft drugs: design principles, success stories, and future perspectives	16
Potential statin drug interactions in elderly patients: a review	16
Ingestion-time – relative to circadian rhythms – differences in the pharmacokinetics and pharmacodynamics of hypertension medications	16
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity	16
GenotypingHLAalleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art	16
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	16
An update on drug–drug interactions between antiretroviral therapies and drugs of abuse in HIV systems	15
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients	15
Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion	14
Assessing the pharmacokinetics and toxicology of polymeric micelle conjugated therapeutics	14
Genetic factors influencing the development of vincristine-induced neurotoxicity	14
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	14
Novel test strategies for in vitro seizure liability assessment	14
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials	14
The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury	13
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	13
Evolving approaches on measurements and applications of intracellular free drug concentration and Kp_uu in drug discovery	12
Pharmacogenomics in Asians: Differences and similarities with other human populations	12
Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation	12
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management	12
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	12
Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response	12
The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models	12
Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs	12
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	12
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review	11
Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs	11
Novel models for the prediction of drug–gene interactions	11
Drug-drug interactions between psychotropic medications and oral contraceptives	11
Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals	11
Positioning the new drugs for migraine	11
Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs	11
Evaluating the risk of manganese-induced neurotoxicity of parenteral nutrition: review of the current literature	11

Coffee in cancer chemoprevention: an updated review	11
An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects	11
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management	11
Xanthones as P-glycoprotein modulators and their impact on drug bioavailability	11
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale	11
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships	11
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	10
Modeling drug transport within the viable skin - a review	10
Circadian regulation of transporter expression and implications for drug disposition	10
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	10
Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism	10
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity	10
Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer	10
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	10
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia	10
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy	10